The Board meeting for approval of Financial statements was rescheduled initially on November 15, 2025 and thenafter on today i.e. November 17, 2025. The Board has approved the unaudited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma reported H1 FY26 (April-September 2025) revenue of Rs. 4.73 crores, up 28.3% YoY from Rs. 3.69 crores in H1 FY25. Despite revenue growth, the company posted a wider net loss of Rs. 2.84 crores for the half-year versus Rs. 2.02 crores loss a year earlier. Q2 FY26 alone turned profitable at Rs. 2.08 crores (EPS Rs. 5.56) versus a loss in the year-ago quarter. The auditor issued a qualified review report flagging that a Rs. 3.5 crore insurance claim linked to a December 2023 fire is still not submitted (awaiting surveyor's report) and that depreciation was not charged on certain damaged plants (cleanroom and effluent treatment). The board meeting was rescheduled from November 15 to November 17.
Negative net worth of -Rs. 68.32 lakhs (worsened from -Rs. 39.89 lakhs at March 2025), negative operating cash flow of -Rs. 3.34 crores in H1, and rising long-term borrowings (Rs. 1.15 crores vs Rs. 77 lakhs earlier) point to ongoing financial stress. The single-quarter profit is encouraging but does not offset structural losses, and the qualified auditor review together with an unresolved insurance claim adds uncertainty. Stock may remain under pressure until profitability and cash generation improve sustainably.